Literature DB >> 3925070

Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness.

H Kawamura, S A Rosenberg, J A Berzofsky.   

Abstract

We studied the effect of purified interleukin 2 (IL-2), made by recombinant DNA techniques, on the serum antibody response to myoglobin in high- and low-responder mice. Previous studies (6, 7) have shown that this response is controlled by H-2-linked Ir genes. The IL-2 was emulsified with the antigen in complete Freund's adjuvant to provide a sustained high local concentration. In low-responder B10.BR mice, a single dose (optimum 50,000 U) resulted in a consistent 10-50-fold increase in specific serum antibody throughout the time course of the response, from 10 d to 46 d after immunization. In contrast, no effect of IL-2 was seen in congenic high-responder B10.D2 mice. With IL-2, the low-responder mice achieved specific antibody levels comparable to those of high responders. Vehicle alone had no effect, and IL-2 alone, without antigen, did not induce myoglobin-specific antibody. No effect of IL-2 was seen in athymic nude mice of high-responder H-2 haplotype. The effect of IL-2 may be on a small number of responding T cells in the low responder mice, but it is possible that IL-2 also acts directly on B cells in a response that remains T-dependent, and therefore is not observed in athymic mice. We suggest that IL-2 may enhance suboptimal T cell help in the low responder, whereas help is not limiting in the high responder. This approach may enable the study of antibody responses in low responders otherwise too weak to analyze, and may be useful in producing antibodies to poorly immunogenic antigens. Potential clinical uses include immunization with weak antigens in normal patients, or with any antigen in certain immunodeficient patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3925070      PMCID: PMC2187696          DOI: 10.1084/jem.162.1.381

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  15 in total

1.  Selective in vitro growth of T lymphocytes from normal human bone marrows.

Authors:  D A Morgan; F W Ruscetti; R Gallo
Journal:  Science       Date:  1976-09-10       Impact factor: 47.728

2.  Genetic control of the immune response to myoglobin. V. Antibody production in vitro is macrophage and T cell-dependent and is under control of two determinant-specific Ir genes.

Authors:  Y Kohno; J A Berzofsky
Journal:  J Immunol       Date:  1982-06       Impact factor: 5.422

3.  In vivo administration of Interleukin-2 enhances specific alloimmune responses.

Authors:  S A Rosenberg; P J Spiess; S Schwarz
Journal:  Transplantation       Date:  1983-06       Impact factor: 4.939

4.  Distinct H-2-linked Ir genes control both antibody and T cell responses to different determinants on the same antigen, myoglobin.

Authors:  J A Berzofsky; L K Richman; D J Killion
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

5.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

6.  The fate of interleukin-2 after in vivo administration.

Authors:  J H Donohue; S A Rosenberg
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

7.  T cell factor (interleukin 2) allows in vivo induction of T helper cells against heterologous erythrocytes in athymic (nu/nu) mice.

Authors:  H Stötter; E Rüde; H Wagner
Journal:  Eur J Immunol       Date:  1980-09       Impact factor: 5.532

8.  Activation of T and B lymphocytes in vitro. II. Biological and biochemical properties of an allogeneic effect factor (AEF) active in triggering specific B lymphocytes.

Authors:  D Armerding; D H Katz
Journal:  J Exp Med       Date:  1974-07-01       Impact factor: 14.307

9.  Genetic control of immune response to myoglobin. Ir gene function in genetic restriction between T and B lymphocytes.

Authors:  Y Kohno; J A Berzofsky
Journal:  J Exp Med       Date:  1982-11-01       Impact factor: 14.307

10.  Expression of Tac antigen on activated normal human B cells.

Authors:  M Tsudo; T Uchiyama; H Uchino
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

View more
  17 in total

Review 1.  Strategies to use immune modulators in therapeutic vaccines against cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; Lauren V Wood
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

Review 2.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 3.  The interleukins in acquired disease.

Authors:  M Malkovský; P M Sondel; W Strober; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

4.  Immunopotentiation of bovine herpes virus subunit vaccination by interleukin-2.

Authors:  H P Hughes; M Campos; D L Godson; S Van Drunen Littel-Van den Hurk; L McDougall; N Rapin; T Zamb; L A Babiuk
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

5.  Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine.

Authors:  J H Nunberg; M V Doyle; S M York; C J York
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

Review 6.  A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses.

Authors:  Jay A Berzofsky
Journal:  Vaccine       Date:  2011-11-21       Impact factor: 3.641

7.  Regulation by recombinant interleukin-2 of protective immunity against recurrent herpes simplex virus type 2 genital infection in guinea pigs.

Authors:  A Weinberg; M Konrad; T C Merigan
Journal:  J Virol       Date:  1987-07       Impact factor: 5.103

8.  In vivo adjuvant effect of interleukins 5 and 6 on rat tear IgA antibody responses.

Authors:  A G Pockley; P C Montgomery
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

9.  Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy.

Authors:  A Schomburg; H Kirchner; J Atzpodien
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

10.  Molecular chimerization of Pasteurella haemolytica leukotoxin to interleukin-2: effects on cytokine and antigen function.

Authors:  H P Hughes; M Campos; A A Potter; L A Babiuk
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.